Highview Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.3M Buy
5,758
+113
+2% +$115K 1.93% 15
2025
Q4
$6.07M Sell
5,645
-122
-2% -$117K 2.14% 12
2025
Q3
$4.4M Sell
5,767
-26
-0.4% -$19.3K 1.62% 15
2025
Q2
$4.52M Buy
5,793
+85
+1% +$66.1K 1.74% 15
2025
Q1
$4.71M Sell
5,708
-1,363
-19% -$1.13M 1.97% 15
2024
Q4
$5.46M Buy
7,071
+308
+5% +$255K 2.1% 14
2024
Q3
$5.99M Buy
6,763
+181
+3% +$163K 2.44% 10
2024
Q2
$5.96M Buy
6,582
+73
+1% +$58.4K 2.48% 10
2024
Q1
$5.06M Sell
6,509
-201
-3% -$143K 2.28% 9
2023
Q4
$3.91M Buy
6,710
+311
+5% +$182K 2.08% 12
2023
Q3
$3.44M Sell
6,399
-69
-1% -$35.6K 1.97% 13
2023
Q2
$3.03M Buy
6,468
+21
+0.3% +$8.81K 1.63% 14
2023
Q1
$2.21M Sell
6,447
-2,236
-26% -$754K 1.28% 17
2022
Q4
$3.18M Buy
8,683
+210
+2% +$74.5K 1.93% 12
2022
Q3
$2.74M Buy
8,473
+712
+9% +$226K 2.03% 12
2022
Q2
$2.52M Sell
7,761
-515
-6% -$155K 1.93% 13
2022
Q1
$2.37M Buy
8,276
+2,405
+41% +$619K 1.52% 15
2021
Q4
$1.62M Buy
+5,871
New +$1.49M 1.05% 22

Other funds holding LLY

Highview Capital Management's LLY Position: Q1 2026 in Review

Highview Capital Management increased its Eli Lilly (LLY) stake by 2% in Q1 2026, buying an estimated $115K and bringing the position to 5,758 shares worth $5.3M. The position accounts for 1.93% of the portfolio, ranked #15.

Highview Capital Management first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. The position peaked at $6.07M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Highview Capital Management held 5,758 shares of Eli Lilly worth $5.3M as of Q1 2026.
  • Highview Capital Management bought 113 Eli Lilly shares in Q1 2026, an estimated $115K.
  • Eli Lilly made up 1.93% of Highview Capital Management's portfolio in Q1 2026, its #15 holding.
  • Highview Capital Management first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
  • Highview Capital Management's Eli Lilly position peaked at $6.07M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Highview Capital Management's 13F filing for Q1 2026, filed 8 May 2026.